首页|前列腺特异性抗原同源异构体2在前列腺癌诊治中的研究进展

前列腺特异性抗原同源异构体2在前列腺癌诊治中的研究进展

扫码查看
前列腺癌是目前全球男性发病率居第二位的恶性肿瘤.在我国其发病率虽然低于欧美国家,但病死率却明显偏高.前列腺特异性抗原同源异构体2(p2PSA)是前列腺特异性抗原(PSA)的前体形式,也是近年新发现的前列腺癌的生物标志物之一,广泛用于前列腺癌的诊断、预测、疗效评估等研究,本文将对近年来p2PSA在前列腺癌诊治中的研究进展作一综述.
Research progress of prostate specific antigen isoform 2 in the diagnosis and treatment of prostate cancer
Prostate cancer is the second malignant tumor in the world with the highest incidence rate of men.In China,although its incidence rate is lower than that of European and American countries,its case fatality rate is sig-nificantly higher.Prostate specific antigen isoform 2(p2PSA)is a precursor form of prostate specific antigen(PSA)and one of the newly discovered biomarkers for prostate cancer in recent years.It is widely used in the diagnosis,pre-diction,and efficacy evaluation of prostate cancer.This article will review the research progress of p2PSA in the diag-nosis and treatment of prostate cancer in recent years.

Prostate specific antigen isoform 2Prostate cancerDiagnosis and treatment

鄢超、令狐志宏、王晶莹、师庆红、焦美玲、王思博、宋丽娜

展开 >

吉林大学中日联谊医院检验科,长春 130033

前列腺特异性抗原同源异构体2 前列腺癌 诊治

2024

中华实验外科杂志
中华医学会

中华实验外科杂志

CSTPCD
影响因子:0.759
ISSN:1001-9030
年,卷(期):2024.41(12)